Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension…
| Price | $2.05 |
|---|---|
| Market cap | $22M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | NASDAQ |
| 52-week range | 1.65-3.07 |
| Beta | 0.27 |
Explore AYTU's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.